September 18, 2012 — Neovasc Inc. announced that acute results from preclinical studies of its Tiara valve for the transcatheter treatment of mitral regurgitation were published in the Journal of the American College of Cardiology (JACC). The study reports that the initial experience with the Tiara transcatheter mitral valve was encouraging, and that implantation of Tiara valves was feasible, relatively straightforward and resulted in a securely-implanted, well-functioning device that maintained good hemodynamics in the test animals. The study, which will be published in the Oct. 9, 2012, edition of JACC, is currently available online.

September 18, 2012 — Abiomed Inc. announced it received confirmation from the American Medical Association (AMA) of three new Category I Current Procedure Terminology (CPT) codes for Impella percutaneous technologies, effective January 2013.

The Cardiovascular Research Foundation (CRF) announced the late-breaking trials and first report investigations that will be presented at next month's Transcatheter Cardiovascular Therapeutics (TCT) 2012 scientific symposium. TCT, the world's premier educational meeting specializing in interventional cardiovascular medicine, will take place Oct. 22-26 in Miami, Fla.

September 13, 2012 — Janssen Research & Development LLC announced that it has submitted the complete response to the U.S. Food and Drug Administration (FDA) for the use of Xarelto (rivaroxaban) to reduce the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS). The response includes specific information requested by the FDA in their letter issued to Janssen on June 21, 2012.